Toronto, Ontario – June 29, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that the Theralase therapeutic laser technology has been proven effective in the treatment of arthritis in recently published animal research. The research was published online May 30, 2017 in Lasers in Medical Science, entitled, “Low-intensity laser therapy efficacy evaluation in FVB mice subjected to acute and chronic arthritis”, authored by Joào Paulo Mardegan Issa, Bianca Ferreira Trawitzki, Edilson Ervolino, Ana Paula Macedo and Lothar Lilge. An abstract to the publication is available here: https://link.springer.com/article/10.1007/s10103-017-2235-5 Rheumatoid arthritis, a chronic inflammatory disorder, has a high prevalence in the population and while therapy is available, it often requires injection of drugs causing discomfort to patients. This study … Read More

Toronto, Ontario – June 26, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that the U.S. Patent and Trademark Office (“USPTO”) has issued a second patent on its lead anti-cancer compound technology licensed by Theralase from Dr. Sherri McFarland. The USPTO granted U.S. Patent Number 9,676,806 B2 entitled, “Metal-Based Thiophene Photodynamic Compounds and Their Use”, which issued on June 13, 2017, as a continuation of U.S. Patent No. 9,345,769. The patent deals with the composition of tunable metal-based thiophene PDCs used as therapeutic agents and as in-vivo diagnostic agents for treating or preventing diseases that involve hyperproliferating cell etiology, including: cancer and diseases associated with hyperproliferating cells. The compositions are also useful for treating infectious diseases … Read More

Toronto, Ontario – June 15, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research on phosphorescent photosensitizers was recently presented on June 12th, at the 16th International Photodynamic Association (“IPA”) World Congress held from June 8th to 13th, 2017 in Coimbra, Portugal. The IPA was founded in 1986 and its membership consists of some of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The IPA promotes the study of diagnosis and clinical treatment using light and Photo Sensitizers (“PSs”), and disseminates this knowledge to IPA members, the medical community and the general public. The IPA World Congress is held every two years and is … Read More

Toronto, Ontario – June 14, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research on X-ray activation of PDCs was recently presented on June 12th, at the 16th International Photodynamic Association (“IPA”) World Congress held from June 8th to 13th, 2017 in Coimbra, Portugal. The IPA was founded in 1986 and its membership consists of some of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The IPA promotes the study of diagnosis and clinical treatment using light and Photo Sensitizers (“PSs”), and disseminates this knowledge to IPA members, the medical community and the general public. The IPA World Congress is held every two … Read More

Toronto, Ontario – June 13, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research on dosimetry planning and Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study data (“Study”) was recently presented on June 9th, at the 16th International Photodynamic Association (“IPA”) World Congress held from June 8th to 13th, 2017 in Coimbra, Portugal. The IPA was founded in 1986 and its membership consists of some of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The IPA promotes the study of diagnosis and clinical treatment using light and Photo Sensitizers (“PSs”), and disseminates this knowledge to IPA members, the medical community and the … Read More

Toronto, Ontario – June 2, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSX-V: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has qualified to trade on the OTCQX® Best Market in the United States. Effective immediately, Theralase has been upgraded to commence trading on the OTCQX market from the Pink® market under the symbol “TLTFF”. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. “Trading on the OTCQX will allow Theralase to build visibility and provide a more transparent market for U.S. investors,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “We are pleased to welcome Theralase to OTCQX and look forward to supporting the company and its shareholders in the public … Read More

Toronto, Ontario – May 30, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that for the three-month period ended March 31, 2017, total revenue increased to $507,428 from $411,448 for the same period in 2016, a 23% increase. In Canada, revenue increased 79% to $322,186 from $180,069 In the US, revenue decreased 7% to $141,714 from $152,375 and international revenue decreased 45% to $43,528 from $79,004. The increase in Canadian revenue in 2017 and the corresponding decrease in US and international revenue is attributable to the Company experiencing slower than expected sales growth of the TLC-2000 in 2016 and 1Q2017, systematically building its sales and marketing teams in the Canadian and then the US market, the learning curves associated with … Read More

Toronto, Ontario – May 26, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the independent Data and Safety Monitoring Board (“DSMB”) has unanimously decided that the primary and secondary objectives for the first part of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) have successfully been met. Princess Margaret Cancer Centre, University Health Network (“UHN”), in accordance with the DSMB’s decision, is now recommended to enroll an additional six patients for the second part of the Study, treating them at a therapeutic dose of the PDC (0.70 mg/kg) for NMIBC using its novel Photo Dynamic Therapy (“PDT”) technology. The DSMB is comprised of three highly regarded, independent uro-oncologists; specifically: Dr. Laurence Klotz of Sunnybrook Health … Read More

Toronto, Ontario – May 1, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that for the year ended December 31, 2016, total revenue decreased to $1,918,893 from $1,945,246 for the same period in 2015, a 1% decrease. In Canada, revenue decreased 16% to $1,423,181 from $1,691,087. In the US, revenue increased 94% to $416,812 from $214,744 and international revenue increased 100% to $78,900 from $39,415. The decrease in Canadian revenue in 2016 and the corresponding increase in US and international revenue is attributable to the Company’s ramp-up of the TLC-2000 therapeutic laser system to commercial volumes, systematically building the sales and marketing teams in the Canadian and US market and the learning curves associated with training and developing a new sales … Read More

Toronto, Ontario – April 20, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the third patient was treated on April 18, 2017 for Non-Muscle Invasive Bladder (“NMIBC”) cancer using its novel Photo Dynamic Therapy (“PDT”) technology. The PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow localization of the PDC to the NMIBC. The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water via a cystoscope. At this point, a fibre optic assembly, known as a Dosimetry Fibre Optic Cage (“DFOC”) with the ability to both emit and … Read More